Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells

International Immunology

Volumn 21, Issue 1, 2009, Pages 53-62

  Casado, Javier G ^a   Delarosa, Olga ^b   Pawelec, Graham ^c   Peralbo, Esther ^b   Duran, Esther ^a   Barahona, Fernando ^d   Solana, Rafael ^b   Tarazona, Raquel ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Cytotoxic T cell differentiation; ELAGIGILTV peptide; Elanoma; Population doubling; T cell expansion

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; MELAN A;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; PHENOTYPE; PRIORITY JOURNAL;

ANTIGENS, CD45; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERFERON-GAMMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 58049208276     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn123     Document Type: Article

References (65)

1. Antonia, S., Mule, J. J. and Weber, J. S. 2004. Current developments of immunotherapy in the clinic. Curr. Opin. Immunol 16:130.
2. Parmiani, G., Castelli, C., Rivoltini, L. et al. 2003. Immunotherapy of melanoma. Semin. Cancer Biol. 13:391.
3. Dudley, M. E. and Rosenberg, S. A. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3:666.
4. Boon, T., Coulie, P. G., Van den Eynde, B. J. and van der, B. P. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24:175.
5. Germeau, C., Ma, W., Schiavetti, F. et al. 2005. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201:241.
6. Lonchay, C., van der, B. P., Connerotte, T. et al. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA 101 (Suppl. 2):14631.
7. Coulie, P. G., Karanikas, V., Lurquin, C. et al. 2002. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 188:33.
8. Ho, W. Y., Yee, C. and Greenberg, P. D. 2002. Adoptive therapy with CD8(+) T cells: It may get by with a little help from its friends. J. Clin. Invest. 110:1415.
9. Blattman, J. N. and Greenberg, P. D. 2004. Cancer immunotherapy: A treatment for the masses. Science 305:200.
10. Ho, W. Y., Nguyen, H. N., Wolfl, M., Kuball, J. and Greenberg, P. D. 2006. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J. Immunol. Methods 310:40.
11. Knutson, K. L., Wagner, W. and Disis, M. L. 2006. Adoptive T cell therapy of solid cancers. Cancer Immunol. Immunother. 55:96.
12. Hinz, T., Buchholz, C. J., van der, S. T., Cichutek, K. and Kalinke, U. 2006. Manufacturing and quality control of cell-based tumor vaccines: A scientific and a regulatory perspective. J. Immunother. 29:472.
13. Wong, R. M., Scotland, R. R., Lau, R. L. et al. 2007. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 19:1223.
14. Matsui, K., O'Mara, L. A. and Allen, P. M. 2003. Successful elimination of large established tumors and avoidance of antigenloss variants by aggressive adoptive T cell immunotherapy. Int. Immunol. 15:797.
15. Iwashiro, M., Jinyan, W., Toda, M., Linan, W., Kato, T. and Kuribayashi, K. 2002. Effective anti-tumor adoptive immunotherapy: Utilization of exogenous IL-2-independent cytotoxic T lymphocyte clones. Int. Immunol. 14:1459.
16. Yee, C. 2003. Adoptive T cell therapy-immune monitoring and MHC multimers. Clin. Immunol. 106:5.
17. Dunbar, P. R., Smith, C. L., Chao, D. et al. 2000. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 165:6644.
18. Geginat, J., Lanzavecchia, A. and Sallusto, F. 2003. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101:4260.
19. Rufer, N., Zippelius, A., Batard, P. et al. 2003. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 102:1779.
20. Sallusto, F., Lenig, D., Forster, R., Lipp, M. and Lanzavecchia, A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708.
21. Lanzavecchia, A. and Sallusto, F. 2005. Understanding the generation and function of memory T cell subsets. Curr. Opin. Immunol. 17:326.
22. Sallusto, F., Geginat, J. and Lanzavecchia, A. 2004. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu. Rev. Immunol. 22:745.
23. Appay, V. and Rowland-Jones, S. L. 2004. Lessons from the study of T-cell differentiation in persistent human virus infection. Semin. Immunol. 16:205.
24. Appay, V., Dunbar, P. R., Callan, M. et al. 2002. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:379.
25. Romero, P., Zippelius, A., Kurth, I. et al. 2007. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J. Immunol. 178:4112.
26. Anichini, A., Scarito, A., Molla, A., Parmiani, G. and Mortarini, R. 2003. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: Role of common gamma-chain cytokines. J. Immunol. 171:2134.
27. Jager, E., Hohn, H., Necker, A. et al. 2002. Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1. Int. J. Cancer 98:376.
28. Valmori, D., Scheibenbogen, C., Dutoit, V. et al. 2002. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 62:1743.
29. Letsch, A., Keilholz, U., Assfalg, G., Mailander, V., Thiel, E. and Scheibenbogen, C. 2003. Bone marrow contains melanomareactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. Cancer Res. 63:5582.
30. Casado, J. G., Soto, R., Delarosa, O. et al. 2005. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol. Immunother 54:1162.
31. D'Souza, S., Rimoldi, D., Lienard, D., Lejeune, F., Cerottini, J. C. and Romero, P. 1998. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int. J. Cancer 78:699.
32. Solana, R., Casado, J. G., Delgado, E. et al. 2007. Lymphocyte activation in response to melanoma: Interaction of NK-associated receptors and their ligands. Cancer Immunol. Immunother 56:101.
33. Mortarini, R., Piris, A., Maurichi, A. et al. 2003. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 63:2535.
34. Romero, P., Dunbar, P. R., Valmori, D. et al. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.
35. Seiter, S., Monsurro, V., Nielsen, M. B. et al. 2002. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J. Immunother. 25:252.
36. Valmori, D., Fonteneau, J. F., Valitutti, S. et al. 1999. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int. Immunol. 11:1971.
37. Pittet, M. J., Valmori, D., Dunbar, P. R. et al. 1999. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:705.
38. Maczek, C., Berger, T. G., Schuler-Thurner, B. et al. 2005. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients. Int. J. Cancer 115:450.
39. Lee, P. P., Yee, C., Savage, P. A. et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677.
40. Valmori, D., Fonteneau, J. F., Lizana, C. M. et al. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750.
41. Lahm, H. W. and Stein, S. 1985. Characterization of recombinant human interleukin-2 with micromethods. J. Chromatogr. 326:357.
42. Montes, M., Rufer, N., Appay, V. et al. 2005. Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin. Exp. Immunol. 142:292.
43. Mansoor, W., Gilham, D. E., Thistlethwaite, F. C. and Hawkins, R. E. 2005. Engineering T cells for cancer therapy. Br. J. Cancer 93:1085.
44. Gattinoni, L., Powell, D. J. Jr., Rosenberg, S. A. and Restifo, N. P. 2006. Adoptive immunotherapy for cancer: Building on success. Nat. Rev. Immunol. 6:383.
45. Speiser, D. E. and Romero, P. 2005. Toward improved immuno-competence of adoptively transferred CD8+ T cells. J. Clin. Invest. 115:1467.
46. Romero, P., Valmori, D., Pittet, M. J. et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188:81.
47. Ayyoub, M., Zippelius, A., Pittet, M. J. et al. 2003. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin. Cancer Res. 9:669.
48. Speiser, D. E., Baumgaertner, P., Voelter, V. et al. 2008. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl Acad. Sci. USA 105:3849.
49. Appay, V., Speiser, D. E., Rufer, N. et al. 2006. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur. J. Immunol. 36:1805.
50. Anichini, A., Vegetti, C. and Mortarini, R. 2004. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol. Immunother. 53:855.
51. Tarazona, R., Casado, J. G., Soto, R. et al. 2004. Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: A two-edged sword? Cancer Immunol. Immunother. 53:911.
52. Pawelec, G. 2004. Tumour escape: Antitumour effectors too much of a good thing? Cancer Immunol. Immunother. 53:262.
53. Pawelec, G. 2004. Immunotherapy and immunoselection - tumour escape as the final hurdle. FEBS Lett. 567:63.
54. Naumova, E., Mihaylova, A., Stoitchkov, K., Ivanova, M., Quin, L. and Toneva, M. 2005. Genetic polymorphism of NK receptors and their ligands in melanoma patients: Prevalence of inhibitory over activating signals. Cancer Immunol. Immunother. 54:172.
55. Naumova, E., Mihaylova, A., Ivanova, M. and Mihailova, S. 2007. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma. Cancer Immunol. Immunother. 56:95.
56. Andrews, D. M., Maraskovsky, E. and Smyth, M. J. 2008. Cancer vaccines for established cancer: How to make them better? Immunol. Rev. 222:242.
57. Welsh, R. M. 2001. Assessing CD8 T cell number and dysfunction in the presence of antigen. J. Exp. Med. 193:F19.
58. June, C. H. 2007. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117:1204.
59. Zhou, J., Shen, X., Huang, J., Hodes, R. J., Rosenberg, S. A. and Robbins, P. F. 2005. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175:7046.
60. Carrasco, J., Godelaine, D., Van, P. A., Boon, T. and van der, B. P. 2006. CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood 108:2897.
61. Huang, J., Khong, H. T., Dudley, M. E. et al. 2005. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28:258.
62. Hinrichs, C. S., Gattinoni, L. and Restifo, N. P. 2006. Programming CD8+ T cells for effective immunotherapy. Curr. Opin. Immunol. 18:363.
63. Klebanoff, C. A., Gattinoni, L. and Restifo, N. P. 2006. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211:214.
64. Gattinoni, L., Klebanoff, C. A., Palmer, D. C. et al. 2005. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115:1616.
65. Dudley, M. E. and Rosenberg, S. A. 2007. Adoptive cell transfer therapy. Semin. Oncol. 34:524.